Anika Therapeutics (ANIK) Stock Price, Quote & News

Company Profile

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 457 9000

Fax: 781 305 9720

Website: www.anika.com

Address:

32 Wiggins Avenue, Bedford, United States

YouOnlyLiveTwice Jul. 30 at 10:03 PM

$ANIK CEO “We delivered a meaningful quarter” I mean the carnage since she became CEO. Single handily destroyed a company that was built by Sherwood and Sylvia What a disgrace ..she needs to be fired and the entire BOD needs to be fired for allowing her to destroy this company

0 · Reply

YouOnlyLiveTwice Jul. 30 at 9:56 PM

$ANIK BK soon

0 · Reply

Messerschmittbf109 Jul. 30 at 7:57 PM

$ANIK thanks ..bad

0 · Reply

breaktime Jul. 30 at 4:25 PM

$ANIK starting to gain a little ground... Based on the latest available information, BlackRock, Inc. owns 6.8% of Anika Therapeutics, Inc. (ANIK) stock

0 · Reply

richardred Jul. 30 at 3:15 PM

$ANIK Ok I’m glad I waited. Bought some today near the low. IMO It’s golden parachute time.

0 · Reply

breaktime Jul. 30 at 2:35 PM

$ANIK added 8.30 now sitting with more than I wanted at 8.80

0 · Reply

Livinglifewithlivingston Jul. 30 at 2:28 PM

$ANIK I’m in

0 · Reply

breaktime Jul. 30 at 2:04 PM

$ANIK way early on the entry, maybe I will be paying for my own lunch and theirs

0 · Reply

breaktime Jul. 30 at 1:54 PM

$ANIK Gonna let these guys pay for lunch

0 · Reply

breaktime Jul. 30 at 1:49 PM

$ANIK in at 9.30. Several institutional investors hold shares of Anika Therapeutics (ANIK). Top institutional holders include Trigran Investments, Inc., BlackRock, Inc., Caligan Partners LP, Vanguard Group Inc, Dimensional Fund Advisors Lp, Acadian Asset Management Llc, Boothbay Fund Management, Llc, Renaissance Technologies Llc, and Alta Fundamental Advisers LLC. 88% institution owned

0 · Reply

Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:05 AM EDT - 15 hours ago

Anika Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 15 hours ago

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update

Jul 16, 2025, 4:01 PM EDT - 14 days ago

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025

Jul 3, 2025, 5:00 PM EDT - 27 days ago

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 11:51 AM EDT - 2 months ago

Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:05 AM EDT - 2 months ago

Anika Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 3 months ago

Anika to Participate in the Sidoti Virtual Investor Conference

Apr 25, 2025, 9:00 AM EDT - 3 months ago

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

Mar 12, 2025, 5:55 PM EDT - 5 months ago

Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:05 PM EDT - 5 months ago

Anika Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 7, 2025, 6:00 AM EST - 5 months ago

Anika Completes Divestiture of Parcus Medical

Feb 26, 2025, 8:00 AM EST - 5 months ago

Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

Feb 25, 2025, 8:00 AM EST - 5 months ago

Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference

Dec 23, 2024, 4:01 PM EST - 7 months ago

Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference

Nov 22, 2024, 4:16 PM EST - 8 months ago

Anika To Participate in December 2024 Investor Conferences

Nov 2, 2024, 9:41 PM EDT - 9 months ago

Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:00 AM EDT - 9 months ago

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Oct 31, 2024, 7:05 AM EDT - 9 months ago

Anika Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 7:00 AM EDT - 9 months ago

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

Oct 17, 2024, 4:01 PM EDT - 10 months ago

Anika Announces Third Quarter 2024 Results Conference Call Date

Aug 11, 2024, 1:49 AM EDT - 1 year ago

Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Anika Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 9:00 AM EDT - 1 year ago

Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 11, 2024, 8:30 AM EDT - 1 year ago

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Jul 1, 2024, 10:35 AM EDT - 1 year ago

Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research

May 28, 2024, 4:05 PM EDT - 1 year ago

Anika Enters into Cooperation Agreement with Caligan Partners

May 8, 2024, 11:36 PM EDT - 1 year ago

Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:08 PM EDT - 1 year ago

Anika Announces CFO Transition

May 8, 2024, 4:05 PM EDT - 1 year ago

Anika Reports First Quarter 2024 Financial Results

Apr 18, 2024, 4:01 PM EDT - 1 year ago

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 13, 2024, 7:17 PM EDT - 1 year ago

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 1 year ago

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024

Feb 13, 2024, 9:00 AM EST - 1 year ago

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

Nov 28, 2023, 9:00 AM EST - 1 year ago

Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release

Nov 7, 2023, 4:05 PM EST - 1 year ago

Anika to Participate in Upcoming Investor Conferences

Nov 3, 2023, 4:34 PM EDT - 1 year ago

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Sep 19, 2023, 9:00 AM EDT - 2 years ago

Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

Sep 12, 2023, 9:00 AM EDT - 2 years ago

Anika to Participate in the Sidoti Small Cap Virtual Investor Conference

Aug 17, 2023, 6:20 PM EDT - 2 years ago

Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Anika Reports Second Quarter 2023 Financial Results

Jul 20, 2023, 4:05 PM EDT - 2 years ago

Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Jul 12, 2023, 9:00 AM EDT - 2 years ago

Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting

May 30, 2023, 4:05 PM EDT - 2 years ago

Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

May 13, 2023, 12:23 PM EDT - 2 years ago

Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:05 PM EDT - 2 years ago

Anika Reports First Quarter 2023 Financial Results

YouOnlyLiveTwice Jul. 30 at 10:03 PM

0 · Reply

YouOnlyLiveTwice Jul. 30 at 9:56 PM

$ANIK BK soon

0 · Reply

Messerschmittbf109 Jul. 30 at 7:57 PM

$ANIK thanks ..bad

0 · Reply

breaktime Jul. 30 at 4:25 PM

$ANIK starting to gain a little ground... Based on the latest available information, BlackRock, Inc. owns 6.8% of Anika Therapeutics, Inc. (ANIK) stock

0 · Reply

richardred Jul. 30 at 3:15 PM

$ANIK Ok I’m glad I waited. Bought some today near the low. IMO It’s golden parachute time.

0 · Reply

breaktime Jul. 30 at 2:35 PM

$ANIK added 8.30 now sitting with more than I wanted at 8.80

0 · Reply

Livinglifewithlivingston Jul. 30 at 2:28 PM

$ANIK I’m in

0 · Reply

breaktime Jul. 30 at 2:04 PM

$ANIK way early on the entry, maybe I will be paying for my own lunch and theirs

0 · Reply

breaktime Jul. 30 at 1:54 PM

$ANIK Gonna let these guys pay for lunch

0 · Reply

breaktime Jul. 30 at 1:49 PM

0 · Reply

PippoBaudo Jul. 30 at 1:43 PM

$ANIK ahahahhaa

0 · Reply

KevZ128 Jul. 30 at 1:34 PM

$ANIK

0 · Reply

Stock_Catcher Jul. 30 at 12:06 PM

$ANIK thin

0 · Reply

OpenOutcrier Jul. 30 at 11:46 AM

$ANIK (-10.3% pre) Anika Reports Mixed Phase 3 Results: Hyalofast Shows Promise Despite Missing Primary Endpoints https://ooc.bz/l/71752

0 · Reply

mebanks Jul. 30 at 11:36 AM

$ANIK , si this oversold? they plan to submit final PMA module in H2 2025- the primary endpoint was not met but it was because of the reason they stated below: "While Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis. Hyalofast exhibited a comparable safety profile when compared to microfracture following the initial effects of the differences in surgical procedure, supporting a favorable benefit-risk profile for Hyalofast." https://elite.finviz.com/news/120350/anika-reports-topline-results-from-us-pivotal-fasttrack-phase-iii-study-for-hyalofast-cartilage-repair-scaffold-and-provides-program-update

0 · Reply

Shriky Jul. 30 at 11:23 AM

@Stock_Catcher Good Morning, Legend! What are your thoughts on $ANIK

0 · Reply

CatCapital_ai Jul. 30 at 11:11 AM

$ANIK Earnings - Q2/2025 Revenue: $28.22M ✅ vs. $27.03M est. EPS: $(0.13) ✅ vs. $(0.26) est. Anika’s Q2 2025 revenue dipped 8%, but regenerative solutions surged 41%, with Integrity implants more than doubling in 2025. The Hyalofast clinical trial missed primary endpoints but showed secondary benefits; final FDA submission planned for late 2025. Long-term Hyalofast launch delayed to 2027, impacting future growth outlook.

0 · Reply

BigSqueezeComing Jul. 30 at 11:07 AM

$ANIK Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast Cartilage Repair Scaffold and Provides Program Update By Anika Therapeutics Inc. | July 30, 2025, 7:00 AM

0 · Reply

DekmarTrades Jul. 30 at 11:05 AM

$ANIK Topline Results on Phase III

1 · Reply

Tarde75 Jul. 30 at 11:02 AM

$ANIK Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update

0 · Reply

BigSqueezeComing Jul. 25 at 5:32 PM

$ANIK pt 12.1

0 · Reply

YouOnlyLiveTwice Jul. 9 at 2:06 PM

$ANIK Coming by for a revisit Sad when Sherwood and Sylvia ran this company they were killing it..:Then Blanchard comes along and destroys it… Not only should she be fired but the entire BOD for allowing her to stay this long. This company is a train wreck

0 · Reply

Market Cap	160.05M
Revenue (ttm)	119.91M
Net Income (ttm)	-56.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-47.03%
Debt to Equity Ratio	0.00

Volume	760,800
Avg Vol	102,262
Day's Range	N/A - N/A
Shares Out	14.34M
Stochastic %K	2%
Beta	0.64
Analysts	Strong Sell
Price Target	$21.33